Krystal Biotech, Inc. (NASDAQ:KRYS) Position Trimmed by Bank of New York Mellon Corp

Bank of New York Mellon Corp decreased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 0.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 169,179 shares of the company’s stock after selling 167 shares during the period. Bank of New York Mellon Corp owned about 0.59% of Krystal Biotech worth $30,503,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Fifth Third Bancorp lifted its stake in Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock valued at $31,000 after buying an additional 105 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Krystal Biotech during the 4th quarter worth $95,000. Covestor Ltd grew its position in Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock valued at $111,000 after buying an additional 642 shares during the period. GAMMA Investing LLC increased its position in shares of Krystal Biotech by 179.3% during the first quarter. GAMMA Investing LLC now owns 673 shares of the company’s stock valued at $121,000 after buying an additional 432 shares during the period. Finally, Elevation Point Wealth Partners LLC purchased a new stake in Krystal Biotech in the first quarter worth approximately $223,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on KRYS. Citigroup reissued a “neutral” rating and issued a $176.00 price objective (up from $155.00) on shares of Krystal Biotech in a research note on Wednesday, July 9th. Guggenheim dropped their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. HC Wainwright restated a “buy” rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Tuesday, June 24th. Finally, Chardan Capital reissued a “buy” rating and issued a $219.00 target price on shares of Krystal Biotech in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $213.75.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 6,927 shares of the stock in a transaction that occurred on Thursday, July 10th. The stock was sold at an average price of $150.27, for a total transaction of $1,040,920.29. Following the transaction, the insider owned 1,525,929 shares of the company’s stock, valued at $229,301,350.83. This trade represents a 0.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In the last quarter, insiders sold 13,927 shares of company stock valued at $2,092,852. Company insiders own 13.70% of the company’s stock.

Krystal Biotech Trading Down 1.8%

Krystal Biotech stock opened at $147.73 on Wednesday. The stock’s 50 day simple moving average is $135.75 and its two-hundred day simple moving average is $156.11. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $219.34. The firm has a market cap of $4.27 billion, a PE ratio of 35.51 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The business had revenue of $88.18 million for the quarter, compared to analysts’ expectations of $98.66 million. On average, equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).